Skip to main content

Media Relations

'Berlin patient' Timothy Brown says he has been cured of HIV; But could it work for others?

Investigators are looking into two main paths toward a cure for AIDS, based  on the stunning stories of a small group of people around the world who have  been able to overcome the disease.

Despite progress in treating millions of people globally with antiretroviral  drugs, experts say a cure is more crucial than ever because the rate of HIV  infections is outpacing the world's ability to medicate people.

"For every person who starts antiretroviral therapy, two new individuals are  infected with HIV," Javier Martinez-Picado of the IrsiCaixa AIDS Research  Institute in Spain told the International AIDS Conference in Washington on  Tuesday.

Some 34 million people around the world are living with HIV, which has  caused around 30 million AIDS-related deaths since the disease first emerged in  the 1980s.

While antiretroviral drugs are helping more people stay alive than ever  before, they are costly and must be taken for life. Experts say only a cure or a  vaccine can make a sufficient dent in the deadly pandemic.

While a cure certainly remains years away, he said scientists can now  "envision a cure from two different perspectives," either by eradicating the  virus from a person's body or coaxing the body to control the virus on its  own.

The most extraordinary case of an apparent cure has been seen in an American  man in his 40s, Timothy  Ray Brown, also known as the "Berlin patient," who was HIV-positive and  developed leukemia.

Brown needed a series of complex medical interventions, including total body  irradiation and two bone marrow transplants that came from a compatible donor  who had a mutation in the CCR5 gene, which acts as a gateway for allowing HIV  into the cells.

People without CCR5 appear to be immune to HIV because, in the absence of  that doorway, HIV cannot penetrate the cells.

"Five years after the (first) transplant the patient remains off  antiretroviral therapy with no viral rebound," said Martinez-Picado.

"This might be the first ever documented patient apparently cured of an HIV  infection."

However, while the case has provided scientists with ample pathways for  research on future gene therapies, the process that appears to have cured Brown  carries a high risk of death and toxicity.

"Unfortunately this type of intervention is so complex and risky it would  not be applicable on a large scale," he said.

Brown announced Tuesday he was launching his own foundation to boost  research toward a cure as the US capital hosts the world's largest scientific  meeting on HIV/AIDS.

"My plan is basically to find donors to get funds to help research and set  up a system to decide who gets the money," said a frail-looking Brown, 47,  adding he planned to dedicate his life to finding a cure for others.

"I am a living proof that there could be a cure for AIDS."

Another group of intense interest is known as the "controllers," or people  whose bodies appear to be able to stave off HIV infection.

One type, known as the "elite controllers," test positive for HIV but do not  appear to have the virus in the blood, even without treatment. Researchers  estimate there may be a few hundred of these people in the world.

Another type is the post-treatment controllers, or people who started  therapy early and are able to stop it without seeing the virus rebound. Some  five to 15 percent of HIV-infected people may fit this category.

More details on a group of "controllers" in France known as the Visconti  Cohort are expected to be released at the meeting this week, as international  scientists share their latest data in the hunt for a cure.

Martinez-Picado also described a "promising" study by US researchers,  published in the journal Nature on Tuesday, that looks into using new drugs to  get rid of the virus when it holes up, or lies dormant in the immune system.

Led by researchers at the University of North Carolina, the small study on  eight HIV-positive men taking antiretrovirals probed how a lymphoma drug,  vorinostat, could activate and disrupt the dormant virus.

Patients who took the drug showed an average 4.5-fold increase in the levels  of HIV RNA in their CD4+ T cells, evidence that the virus was being unmasked,  demonstrating a new potential strategy for attacking latent HIV infection.

"We now actively talk of potential scientific solutions in a way perhaps we  weren't some years ago," said Diane Havlir, AIDS 2012 US co-chair and professor  of medicine at the University of California, San Francisco

Read more:

All News  Now Viewing Category: All
School of Journalism & Broadcasting
Kinesiology, Recreation & Sport
Media Relations
Academic Affairs
Augenstein Alumni Center
Instruments of American Excellence
Emergency Preparedness
Department of Music
Department of Theatre & Dance
Library News
Office of Sustainability
Office of International Programs
Office of Research
Ogden News
WKU Greeks News
WKU Parent and Family Weekend
Parent's Association
Student Activities and Organizations
Scholarships Student Financial Assistance
Student Government Association News
Van Meter Auditorium
Teaching News
Study Abroad
Student Research Council
Student Employment
WKU Joint Admissions
International Student Office
Human Resources News
Cultural Enhancement Series
The Confucius Institute
Campus Activities Board
The Gatton Academy of Mathematics and Science in Kentucky
Development and Alumni Relations
Downing Student Union
Health Services
Hardin Planetarium
News from The Center for Gifted Studies
Student Financial Assistance
Downing Museum
Etown & Fort Knox
Employee Wellness
Latest Headlines
WKU steel bridge team making fourth consecutive trip to national competition May 27-28
WKU group attends planning association conference

Last week WKU faculty, students and alumni attended the Kentucky Chapter of the American Planning Association conference at the Sloan Convention Center in Bowling Green.

WKU group attends planning association conference
Featured Articles
Enactus Team Competes in Nationals
Summer 2016 WKU Operating Hours

Need to reach us over the summer? Don't forget that our hours change! Click to find full dates and times of opening.

Eura Shin Receives Scholarship for Research Internship in Germany

Eura Shin, a second-year student at The Gatton Academy, has received a funded summer internship in Germany through a competitive, international scholarship.

Note: documents in Portable Document Format (PDF) require Adobe Acrobat Reader 5.0 or higher to view,
download Adobe Acrobat Reader.

Note: documents in Excel format (XLS) require Microsoft Viewer,
download excel.

Note: documents in Word format (DOC) require Microsoft Viewer,
download word.

Note: documents in Powerpoint format (PPT) require Microsoft Viewer,
download powerpoint.

Note: documents in Quicktime Movie format [MOV] require Apple Quicktime,
download quicktime.

 Last Modified 9/24/14